𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Combined paclitaxel, cisplatin, and etoposide for patients with previously untreated esophageal and gastroesophageal carcinomas

✍ Scribed by Jacob J. Lokich; Henry Sonneborn; Norwood R. Anderson; Murray M. Bern; Frank V. Coco; Edward Dow; Peter Oliynyk

Publisher
John Wiley and Sons
Year
1999
Tongue
English
Weight
61 KB
Volume
85
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis

BACKGROUND. Paclitaxel (T), etoposide (E), and cisplatin (P) are each active in gastric carcinoma, either as single agents or as part of a multidrug regimen. To the authors' knowledge, the combination of these three agents in the treatment of patients with esophageal or gastroesophageal carcinoma has not been previously studied.

METHODS.

Previously untreated patients with locally advanced carcinoma of the stomach, esophagus, or gastroesophageal (GE) junction received at least 2 cycles of TPE administered twice weekly for 3 weeks, with the cycle repeated every 28 days.

Drug doses, administered over 3 hours on either Monday and Thursday or Tuesday and Friday, consisted of T 50 mg/m 2 /dose, P 15 mg/m 2 /dose, and E 40 mg/m 2 / dose. For patients with local disease only, subsequent therapy consisted of radiation with or without surgical resection.

πŸ“œ SIMILAR VOLUMES

Concurrent cisplatin, paclitaxel, and ra
Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma
✍ Susan G. Urba; Mark B. Orringer; Mark Ianettonni; James A. Hayman; Hayasaka Sato πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 87 KB

## Abstract ## BACKGROUND A Phase II trial was conducted at the University of Michigan to determine the efficacy of a preoperative regimen of concurrent cisplatin, paclitaxel, and radiation for patients with locoregional esophageal carcinoma. ## METHODS Sixty‐nine patients with esophageal carcin

Effective radiochemotherapy with cisplat
Effective radiochemotherapy with cisplatin and etoposide for the management of patients with locally inoperable and metastatic esophageal carcinoma
✍ Michael Hejna; Gabriela V. Kornek; Annemarie U. Schratter-Sehn; Malgorzata Zach; πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 545 KB

## BACKGROUND. The limited therapeutic value of available chemotherapeutic drug combinations in patients with advanced esophageal carcinoma, the documented synergistic activity of etoposide and cisplatin, which might be further enhanced by simultaneous radiotherapy, and promising though only preli

Capecitabine in combination with docetax
Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma
✍ Marco Venturini; Antonio Durando; Ornella Garrone; Maria Antonietta Colozza; Ant πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 103 KB πŸ‘ 1 views

## Abstract ## BACKGROUND The objective of this study was to evaluate the activity and safety of oral capecitabine in combination with docetaxel and epirubicin (TEX) as first‐line treatment for patients with locally advanced/metastatic breast carcinoma. ## METHODS This open‐label, Phase II study

Phase II trial of irinotecan, paclitaxel
Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma
✍ Mark A. Socinski; Alan B. Sandler; Valerie K. Israel; Heidi H. Gillenwater; Lang πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 86 KB πŸ‘ 1 views

## Abstract ## BACKGROUND This Phase II multicenter, open‐label, single‐arm study evaluated the efficacy and safety of a three‐drug combination of irinotecan (CPT‐11), paclitaxel, and carboplatin in advanced nonsmall cell lung carcinoma (NSCLC). ## METHODS Patients received repeated 21‐day cycle